



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Anna Sundlöv**

Organisation/Company: Medical Products Agency

Country: Sweden

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

Period	Company	Category	Products	Therapeutic Indication
10/2018-03/2021	Synapticon AB	Executive role	Founder and senior consultant	

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2015-03/2021	Spago Nanomedical AB	SpagoPix and Tumorad	MRI contrast medium for tumor diagnostic imaging (SpagoPix) and radiolabelled nanoparticle for antitumor therapy (Tumorad).
01/2018-12/2020	Sam Nordic	Lecturer and moderator and coordinator of webinars on radionuclide therapy and/or neuroendocrine tumors.	
01/2016-12/2019	Ipsen	Lecturer on neuroendocrine tumors, treatment strategies, radionuclide therapy, etc	
09/2020-12/2020	AAA/Endocyte/Novartis	Lecturer on radionuclide therapy, personalization strategies, dosimetry, etc.	

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
09/2020-11/2020	AAA/Endocyte/Novartis	177Lu-PSMA	Prostate cancer

Classified as public by the European Medicines Agency

2

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2018-03/2021	AAA/Endocyte/Novartis	177Lu-PSMA617 (VISION trial, national coordinating investigator Sweden)	Prostate cancer

2.7 Grant / Funding to organisation /institution

No interest declared

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

I currently have a part-time employment as a researcher at the Department of Clinical Sciences, Division of Oncology, at Lund University, Sweden.

I have been involved in a publicly funded, academic clinical trial studying personalized treatment of neuroendocrine tumors using 177Lu-DOTATOC. The trial will be conducted in 2022-2026. My involvement was terminated in March 2022, before any patients had been included in the trial. The trial has received academic grants by the Swedish Research Council (?2M) and the Berta Kamprad Foundation (?200.000). I was a co-applicant and main applicant, respectively, for these grants. The administration of them has been transferred to the other co-applicants.

I am currently involved in the data analysis of a publicly funded, academic clinical trial studying personalized treatment of neuroendocrine tumors using 177Lu-DOTATATE. The trial was conducted in 2011-2019. Publication is expected in 2022 with myself as first author.

I was the principal investigator of an academic clinical trial using the PET-tracer 68Ga-DOTATATE for the study of patients with metastatic neuroendocrine tumors. The trial was conducted in 2013-2016. The results have been published and the trial archived.

I was the national coordinating investigator in the academic clinical trial ET-NEC which studied antitumor treatment with everolimus and temozolomide in patients with neuroendocrine carcinoma. The trial was conducted in 2015-2018. Data is currently being analyzed and publication is expected in 2022.

My husband has an executive role in a biotechnology company which does not, however, have any activity related to ATMPs.

Classified as public by the European Medicines Agency

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Anna Sundlöv
Date:	2022-03-08

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template